ZF Friedrichshafen, einer der größten Automobilzulieferer weltweit, steht unter erheblichem wirtschaftlichen Druck. Als Reaktion auf die angespannte Lage wird am Stammsitz des Konzerns in Friedrichsha ...

An der Börse notiert die Aktie von Ramelius Resources zur Stunde leichter. Das Papier notiert gegenwärtig bei 1,48 Euro. Das Wertpapier von Ramelius Resources verzeichnet derzeit einen Abschlag von 1, ...

Team, Inc. (NYSE: TISI) ("TEAM" or the "Company"), a global, leading provider of specialty industrial services offering customers access to a full ...

Exodus Movement, Inc. (NYSE American: EXOD) ("Exodus"), a leading self-custodial cryptocurrency platform, today announced its unaudited results for the first ...

Total revenue increased 17% to $134.1 million Net income of $8.0 million at a 6% margin; adjusted EBITDA of $41.5 million at a 31% margin Raises midpoint of full-year ...

Matthews Memorialization, a division of Matthews International Corporation (NASDAQ GSM: MATW) ("Matthews"), today announced it has acquired The Dodge Company ...

HighPeak Energy, Inc. ("HighPeak" or the "Company") (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2025 ...

Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r ...

First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinica ...

Active Users Reached Approximately 83.7 millionRecord Q1 Global Net Additions to Paying Circles of 137 thousand - Reaching 2.4 million TotalTotal Quarterly Revenue Grew 32% Year-Over-Year to ...

Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are ...

Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additi ...